Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Mark Cuban: Mixing Up the Pharmaceutical Landscape

Catherine Kolonko  |  Issue: April 2023  |  April 7, 2023

The Mark Cuban Cost Plus Drug Co. (CPD) launched in January 2022 to distribute and home deliver prescribed generic medications to consumers. The Texas-based business seeks to reduce the prices of generic drugs by leapfrogging financial negotiators and going straight to drug companies for supply, according to a news release.1

“It’s crazy that medications are priced the way they are,” investor Mark Cuban told The Rheumatologist. “The pricing process has been distorted by the big incumbents.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Costplusdrugs.com was created to work outside the existing system, bringing transparency and cost plus pricing to patients. We think this will bring about structural change.”

When CPD’s online pharmacy first opened, it had an inventory of 100 generic drugs. Over the following months, that number grew to 1,000 or more, according to recent accounts by company officials.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Customers can visit costplusdrugs.com to find out if their prescription is offered and how much CPD charges for the drug. Anyone who wants to order must provide an email address, and request and obtain a new prescription from “a U.S.-based provider,” before the medication can be mailed, according to the website.2

Price examples of a drug from CPD vs. retail prices at other unnamed companies are posted on the company website. Low prices are maintained by cutting out pharmacy benefit managers (PBMs) and negotiating directly with drug manufacturers, according to CPD website FAQs.3

“We’re different from your normal drug wholesaler. We think you should know how much your medications cost and why,” states the company on the website.

An example CPD price on its website shows the drug imatinib for leukemia as $39 for 30 tablets (400 mg), compared with a retail price of more than $9,000. GoodRx.com, another online prescription service, lists the same drug price at $119, with a specific pharmacy coupon, compared with an average retail price of $4,430.2,4

Cash Model

Mark Cuban

Mr. Cuban entered the prescription drug arena to assist businesses that provide medications coverage within their employee benefit plans, according to the news release. The company model is to operate online and offer cash customers prescription medications at 15 percent above wholesale price, plus minimal shipping and labor fees.1 Plans call for adding insurance as a payment option in the future.

It is as much the cachet as the cash that the billionaire Mr. Cuban brings to the table in the world of PBMs, according to Robert Popovian, PharmD, MS, chief science policy officer for Global Healthy Living Foundation. Other companies, such as Costco, have cash payment models similar to CPD, says the pharmacist who coauthored a white paper with the Schaeffer Center about how consumers overpay for generic medications and the merits of paying with cash.5

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Drug Updates Tagged with:pharmacy benefit managersprescription drug prices

Related Articles

    Super-Group Physician Practices Offer Benefits, But Raise Concerns

    June 15, 2015

    Rheumatologists worried about the future of their private practices might want to consider jumping onto the super group trend that allows physicians and other providers with similar services to team up to share opportunities and minimize financial burdens. The biggest concern for private practice physicians watching the trend but not yet embracing it is fear…

    Generic-Drug Price Fixing: Is It Happening?

    May 17, 2018

    It started with an inhaler. Like many of you, I am a rheuma­tologist. And like you, I see some patients more often their own primary care provider. This is so often the case that I have gradually devolved into their backup, all-purpose doctor. I am the doc they notify when they get hospitalized for pneumonia…

    The Cost of Free Pharmaceutical Services

    October 18, 2019

    The cards sat, untouched, in a corner of my desk. In the 1800s, it was common for American saloons to provide patrons with a free meal. Of course, the meal came with a catch: The meals were predictably salt laden and designed to encourage patrons to drink more beer. Hence was born the expression, “There…

    High Cost of Specialty Drugs Demands Action

    July 6, 2021

    Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences